IRIS
IRIS Home | Critical Effect Search Results
Searches using filters for organ/system affected are limited to effects (or tumor sites) used to derive the
RfD, RfC, oral slope factor, or inhalation unit risk.
Other effects associated with chemicals in the IRIS database that were not used as the basis for a toxicity value are not searchable with
organ/system filters. IRIS Advanced Search searches only final IRIS assessments; to look for information on draft assessments, see
Quick Check: Assessments in Development.
Search Filtered by: Critical Effect = "Hepatic"
Number of records: 130
| Chemical Name | CASRN | Exposure Route | Critical Effect | RfD/RfC | RfD/RfC Value |
|---|---|---|---|---|---|
| Acenaphthene | 83-32-9 | Oral | Hepatotoxicity | RFD | 6 x 10 -2 mg/kg-day |
| Acetochlor | 34256-82-1 | Oral | Salivation, increased ALT and ornithine carbamyl transferase; significant increases in triglyceride and decreased blood glucose levels; histopathological changes in kidneys and testes of males | RFD | 2 x 10 -2 mg/kg-day |
| Aldrin | 309-00-2 | Oral | Liver toxicity | RFD | 3 x 10 -5 mg/kg-day |
| Allyl alcohol | 107-18-6 | Oral | Impaired renal function and increased liver and kidney weights | RFD | 5 x 10 -3 mg/kg-day |
| Amdro | 67485-29-4 | Oral | Increased organ weights | RFD | 3 x 10 -4 mg/kg-day |
| Ametryn | 834-12-8 | Oral | Liver toxicity | RFD | 9 x 10 -3 mg/kg-day |
| Apollo | 74115-24-5 | Oral | Liver effects; organ weight changes | RFD | 1.3 x 10 -2 mg/kg-day |
| Assure | 76578-14-8 | Oral | Liver cell enlargement | RFD | 9 x 10 -3 mg/kg-day |
| Asulam | 3337-71-1 | Oral | Lower ovarian weight, lower liver/body weight | RFD | 5 x 10 -2 mg/kg-day |
| Benzidine | 92-87-5 | Oral | Brain cell vacuolization; liver cell alterations in females | RFD | 3 x 10 -3 mg/kg-day |
| Bromobenzene | 108-86-1 | Oral | Hepatocellular cytomegaly in male B6C3F1 mice | RFD | 2 x 10 -2 mg/kg-day |
| Bromobenzene | 108-86-1 | Inhalation | Hepatocellular cytomegaly in female B6C3F1 mice | RFC | 6 x 10 -2 mg/m3 |
| Bromobenzene | 108-86-1 | Inhalation | Hepatocellular cytomegaly in female B6C3F1 mice | RFC | 2 x 10 -1 mg/m3 |
| Bromobenzene | 108-86-1 | Oral | Hepatocellular cytomegaly in male B6C3F1 mice | RFD | 8 x 10 -3 mg/kg-day |
| Bromoform | 75-25-2 | Oral | Hepatic lesions | RFD | 2 x 10 -2 mg/kg-day |
| Butyl benzyl phthalate (BBP) | 85-68-7 | Oral | Significantly increased liver-to-body weight and liver-to-brain weight ratios | RFD | 2 x 10 -1 mg/kg-day |
| Butylate | 2008-41-5 | Oral | Increased relative liver weight in male dogs | RFD | 5 x 10 -2 mg/kg-day |
| Carbaryl | 63-25-2 | Oral | Kidney and liver toxicity | RFD | 1 x 10 -1 mg/kg-day |
| Carbon tetrachloride | 56-23-5 | Oral | Elevated serum SDH activity | RFD | 4 x 10 -3 mg/kg-day |
| Carbon tetrachloride | 56-23-5 | Inhalation | Fatty changes in the liver | RFC | 1 x 10 -1 mg/m3 |
| Chloramben | 133-90-4 | Oral | Hepatocyte degeneration | RFD | 1.5 x 10 -2 mg/kg-day |
| Chlordane (Technical) | 12789-03-6 | Inhalation | Hepatic effects | RFC | 7 x 10 -4 mg/m3 |
| Chlordane (Technical) | 12789-03-6 | Oral | Hepatic necrosis | RFD | 5 x 10 -4 mg/kg-day |
| Chlorobenzene | 108-90-7 | Oral | Histopathologic changes in liver | RFD | 2 x 10 -2 mg/kg-day |
| Chloroform | 67-66-3 | Oral | Moderate/marked fatty cyst formation in the liver and elevated SGPT | RFD | 1 x 10 -2 mg/kg-day |
| beta-Chloronaphthalene | 91-58-7 | Oral | Dyspnea, abnormal appearance, liver enlargement | RFD | 8 x 10 -2 mg/kg-day |
| Chlorpropham | 101-21-3 | Oral | Kidney, spleen, liver, and bone marrow toxicity | RFD | 2 x 10 -1 mg/kg-day |
| Copper cyanide | 544-92-3 | Oral | Decreased body and organ weights, histopathologic alterations in liver and kidney | RFD | 5 x 10 -3 mg/kg-day |
| Dacthal | 1861-32-1 | Oral | Effects on the lungs, liver, kidney, thyroid and thyroid hormones in males and females and eyes of females | RFD | 1 x 10 -2 mg/kg-day |
| Di (2-ethylhexyl)phthalate (DEHP) | 117-81-7 | Oral | Increased relative liver weight | RFD | 2 x 10 -2 mg/kg-day |
| Di(2-ethylhexyl)adipate | 103-23-1 | Oral | Changes in body weight and liver weight increased liver weight of male and female parents reduced ossification and slightly dilated ureters in fetuses reduced offspring weight gain, total litter weight, and litter size | RFD | 6 x 10 -1 mg/kg-day |
| 1,4-Dibromobenzene | 106-37-6 | Oral | Liver/body weight ratio and hepatic microsomal enzyme induction | RFD | 1 x 10 -2 mg/kg-day |
| Dibromochloromethane | 124-48-1 | Oral | Hepatic lesions | RFD | 2 x 10 -2 mg/kg-day |
| 1,2-Dibromoethane | 106-93-4 | Oral | Testicular atrophy, liver peliosis, and adrenal cortical degeneration | RFD | 9 x 10 -3 mg/kg-day |
| Dichloroacetic acid | 79-43-6 | Oral | Lesions observed in the testes, cerebrum, cerebellum, and liver. | RFD | 4 x 10 -3 mg/kg-day |
| 1,4-Dichlorobenzene | 106-46-7 | Inhalation | Increased liver weights in P1 males | RFC | 8 x 10 -1 mg/m3 |
| p,p'-Dichlorodiphenyltrichloroethane (DDT) | 50-29-3 | Oral | Liver lesions | RFD | 5 x 10 -4 mg/kg-day |
| 1,1-Dichloroethylene (1,1-DCE) | 75-35-4 | Oral | Liver toxicity (fatty change) | RFD | 5 x 10 -2 mg/kg-day |
| 1,1-Dichloroethylene (1,1-DCE) | 75-35-4 | Inhalation | Liver toxicity (fatty change) | RFC | 2 x 10 -1 mg/m3 |
| Dichloromethane | 75-09-2 | Inhalation | Hepatic effects (hepatic vacuolation) | RFC | 6 x 10 -1 mg/m3 |
| Dichloromethane | 75-09-2 | Oral | Hepatic effects (hepatic vacuolation, liver foci) | RFD | 6 x 10 -3 mg/kg-day |
| 2,4-Dichlorophenoxyacetic acid (2,4-D) | 94-75-7 | Oral | Hematologic, hepatic and renal toxicity | RFD | 1 x 10 -2 mg/kg-day |
| 2,3-Dichloropropanol | 616-23-9 | Oral | Myocardial degeneration, hepatotoxicity and nephrotoxicity | RFD | 3 x 10 -3 mg/kg-day |
| Dieldrin | 60-57-1 | Oral | Liver lesions | RFD | 5 x 10 -5 mg/kg-day |
| Dimethipin | 55290-64-7 | Oral | Increased absolute and relative liver weight | RFD | 2 x 10 -2 mg/kg-day |
| N,N-Dimethylformamide | 68-12-2 | Inhalation | Digestive disturbances and minimal hepatic changes suggestive of liver abnormalities | RFC | 3 x 10 -2 mg/m3 |
| 2,6-Dimethylphenol | 576-26-1 | Oral | Body weight changes and histopathological changes of internal organs (liver, spleen and kidneys) | RFD | 6 x 10 -4 mg/kg-day |
| 3,4-Dimethylphenol | 95-65-8 | Oral | Changes in blood pressure and body weight histopathological changes in liver, kidney and spleen | RFD | 1 x 10 -3 mg/kg-day |
| 2,4-Dinitrotoluene | 121-14-2 | Oral | Neurotoxicity, Heinz bodies and biliary tract hyperplasia | RFD | 2 x 10 -3 mg/kg-day |
| 1,4-Dioxane | 123-91-1 | Oral | Liver and kidney toxicity | RFD | 3 x 10 -2 mg/kg-day |
| Diphenamid | 957-51-7 | Oral | Liver toxicity | RFD | 3 x 10 -2 mg/kg-day |
| Diphenylamine | 122-39-4 | Oral | Decreased body weight gain, and increased liver and kidney weights | RFD | 2.5 x 10 -2 mg/kg-day |
| Endrin | 72-20-8 | Oral | Mild histological lesions in liver, occasional convulsions | RFD | 3 x 10 -4 mg/kg-day |
| Ethylbenzene | 100-41-4 | Oral | Liver and kidney toxicity | RFD | 1 x 10 -1 mg/kg-day |
| Fluoranthene | 206-44-0 | Oral | Nephropathy, increased liver weights, hematological alterations, and clinical effects | RFD | 4 x 10 -2 mg/kg-day |
| Flurprimidol | 56425-91-3 | Oral | Increased incidence of hepatocellular changes including fatty change and vacuolation (M) increased susceptibility to stress factors (F) | RFD | 2 x 10 -2 mg/kg-day |
| Flutolanil | 66332-96-5 | Oral | Decreased body weight and body weight gains in both doses increased liver weights at high dose | RFD | 6 x 10 -2 mg/kg-day |
| Folpet | 133-07-3 | Oral | Decreased body weight gain, altered serum chemistry parameters (decreased serum cholesterol, total protein, and serum albumin and globulin levels) | RFD | 1 x 10 -1 mg/kg-day |
| Fonofos | 944-22-9 | Oral | Cholinesterase inhibition, cholinergic symptoms, and increased liver weight | RFD | 2 x 10 -3 mg/kg-day |
| Furan | 110-00-9 | Oral | Hepatic lesions | RFD | 1 x 10 -3 mg/kg-day |
| Furfural | 98-01-1 | Oral | Mild hepatocellular vacuolization | RFD | 3 x 10 -3 mg/kg-day |
| Heptachlor | 76-44-8 | Oral | Liver weight increases in males | RFD | 5 x 10 -4 mg/kg-day |
| Heptachlor epoxide | 1024-57-3 | Oral | Increased liver-to-body weight ratio in both males and females | RFD | 1.3 x 10 -5 mg/kg-day |
| Hexabromobenzene | 87-82-1 | Oral | Induced serum carboxylesterase activity, increased relative liver weight, increased liver porphyrins | RFD | 2 x 10 -3 mg/kg-day |
| Hexachlorobenzene | 118-74-1 | Oral | Liver effects | RFD | 8 x 10 -4 mg/kg-day |
| gamma-Hexachlorocyclohexane (gamma-HCH) | 58-89-9 | Oral | Liver and kidney toxicity | RFD | 3 x 10 -4 mg/kg-day |
| Imazaquin | 81335-37-7 | Oral | Decreased body weight gain, skeletal myopathy, slight anemia, bone marrow hyperplasia, elevated serum SGOT, SGPT, CPK | RFD | 2.5 x 10 -1 mg/kg-day |
| Isoxaben | 82558-50-7 | Oral | Increased BUN; decreased serum AP and AST; decreased food consumption efficiency; increased heart/body weight | RFD | 5 x 10 -2 mg/kg-day |
| Lactofen | 77501-63-4 | Oral | Increased absolute and relative liver weight; hepatocytomegaly in males | RFD | 2 x 10 -3 mg/kg-day |
| Londax | 83055-99-6 | Oral | Liver effects | RFD | 2 x 10 -1 mg/kg-day |
| Metalaxyl | 57837-19-1 | Oral | Increased serum alkaline phosphatase levels and increased liver-to-brain weight ratio | RFD | 6 x 10 -2 mg/kg-day |
| Methacrylonitrile | 126-98-7 | Oral | Increased SGOT and SGPT levels | RFD | 1 x 10 -4 mg/kg-day |
| Methidathion | 950-37-8 | Oral | Liver toxicity | RFD | 1 x 10 -3 mg/kg-day |
| Methyl tert-butyl ether (MTBE) | 1634-04-4 | Inhalation | Increased absolute and relative liver and kidney weights and increased severity of spontaneous renal lesions (females), increased prostration (females), and swollen periocular tissue (males and females) | RFC | 3 mg/m3 |
| 4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB) | 94-81-5 | Oral | Male reproductive toxicity and other effects (including decreased body weight gain), increased liver and kidney weights | RFD | 1 x 10 -2 mg/kg-day |
| 2-Methyl-4-chlorophenoxyacetic acid (MCPA) | 94-74-6 | Oral | Kidney and liver toxicity | RFD | 5 x 10 -4 mg/kg-day |
| Metribuzin | 21087-64-9 | Oral | Liver and kidney effects, decreased body weight, mortality | RFD | 2.5 x 10 -2 mg/kg-day |
| Mirex | 2385-85-5 | Oral | Liver cytomegaly, fatty metamorphosis, angiectasis; thyroid cystic follicles | RFD | 2 x 10 -4 mg/kg-day |
| 2-Nitropropane | 79-46-9 | Inhalation | Liver focal vacuolization and nodules | RFC | 2 x 10 -2 mg/m3 |
| Norflurazon | 27314-13-2 | Oral | Liver and thyroid effects | RFD | 4 x 10 -2 mg/kg-day |
| NuStar | 85509-19-9 | Oral | Liver cell enlargement | RFD | 7 x 10 -4 mg/kg-day |
| Octabromodiphenyl ether | 32536-52-0 | Oral | Induction of hepatic enzymes; liver histopathology | RFD | 3 x 10 -3 mg/kg-day |
| Octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine (HMX) | 2691-41-0 | Oral | Hepatic lesions | RFD | 5 x 10 -2 mg/kg-day |
| Oryzalin | 19044-88-3 | Oral | Increases in serum cholesterol, alkaline phosphatase, and relative liver and kidney weights, and decreases in alanine transaminase and adrenal weights | RFD | 5 x 10 -2 mg/kg-day |
| Oxadiazon | 19666-30-9 | Oral | Increased levels of serum proteins and increased liver weights | RFD | 5 x 10 -3 mg/kg-day |
| Oxyfluorfen | 42874-03-3 | Oral | Increased absolute liver weight and nonneoplastic lesions | RFD | 3 x 10 -3 mg/kg-day |
| Paclobutrazol | 76738-62-0 | Oral | Elevated liver weights, serum cholesterol, hepatic aminopyrine N-demethylase activity, and alanine transaminase levels | RFD | 1.3 x 10 -2 mg/kg-day |
| Pendimethalin | 40487-42-1 | Oral | Increase in serum alkaline phosphatase and liver weight, and hepatic lesions | RFD | 4 x 10 -2 mg/kg-day |
| Pentabromodiphenyl ether | 32534-81-9 | Oral | Induction of hepatic enzymes | RFD | 2 x 10 -3 mg/kg-day |
| Pentachlorobenzene | 608-93-5 | Oral | Liver and kidney toxicity | RFD | 8 x 10 -4 mg/kg-day |
| Pentachloronitrobenzene (PCNB) | 82-68-8 | Oral | Liver toxicity | RFD | 3 x 10 -3 mg/kg-day |
| Pentachlorophenol | 87-86-5 | Oral | Hepatotoxicity | RFD | 5 x 10 -3 mg/kg-day |
| Perfluorobutanoic Acid (PFBA) | 375-22-4 | Oral | Increased hepatocellular hypertrophy (Liver), Decreased total T4 (Thyroid) | RFD | 1 x 10 -3 mg/kg-day |
| Perfluorobutanoic Acid (PFBA) | 375-22-4 | Oral | Increased hepatocellular hypertrophy | RFD | 1 x 10 -2 mg/kg-day |
| Perfluorobutanoic Acid (PFBA) | 375-22-4 | Oral | Increased hepatocellular hypertrophy | RFD | 1 x 10 -3 mg/kg-day |
| Perfluorohexanoic Acid (PFHxA) | 307-24-4 | Oral | Increased hepatocellular hypertrophy in adult male Crl:CD Sprague‑Dawley rats | RFD | 4 x 10 -4 mg/kg-day |
| Perfluorohexanoic Acid (PFHxA) | 307-24-4 | Oral | Increased hepatocellular hypertrophy in adult rats | RFD | 1 x 10 -3 mg/kg-day |
| Permethrin | 52645-53-1 | Oral | Increased liver weights | RFD | 5 x 10 -2 mg/kg-day |
| m-Phenylenediamine | 108-45-2 | Oral | Increased relative and absolute liver weights and degenerative liver lesions | RFD | 6 x 10 -3 mg/kg-day |
| Phosmet | 732-11-6 | Oral | Reduced body weight (males), liver cell vacuolation, cholinesterase inhibition | RFD | 2 x 10 -2 mg/kg-day |
| Picloram | 1918-02-1 | Oral | Increased liver weights | RFD | 7 x 10 -2 mg/kg-day |
| Prochloraz | 67747-09-5 | Oral | Increase in SAP and liver weights, liver histopathology | RFD | 9 x 10 -3 mg/kg-day |
| Prometryn | 7287-19-6 | Oral | Liver and kidney degeneration and bone marrow atrophy | RFD | 4 x 10 -3 mg/kg-day |
| Propachlor | 1918-16-7 | Oral | Decreased weight gain, food consumption increased relative liver weights | RFD | 1.3 x 10 -2 mg/kg-day |
| Propargyl alcohol | 107-19-7 | Oral | Renal and hepatotoxicity | RFD | 2 x 10 -3 mg/kg-day |
| Pyridine | 110-86-1 | Oral | Increased liver weight | RFD | 1 x 10 -3 mg/kg-day |
| Styrene | 100-42-5 | Oral | Red blood cell and liver effects | RFD | 2 x 10 -1 mg/kg-day |
| Terbacil | 5902-51-2 | Oral | Increase in thyroid/body weight ratio; slight increase in liver weights; elevated alkaline phosphatase | RFD | 1.3 x 10 -2 mg/kg-day |
| 1,1,2,2-Tetrachloroethane | 79-34-5 | Oral | Increased relative liver weight in rats | RFD | 5 x 10 -2 mg/kg-day |
| 1,1,2,2-Tetrachloroethane | 79-34-5 | Oral | Increased relative liver weight in rats | RFD | 2 x 10 -2 mg/kg-day |
| 1,1,1,2-Tetrachloroethane | 630-20-6 | Oral | Mineralization of the kidneys in males, hepatic clear cell change in females | RFD | 3 x 10 -2 mg/kg-day |
| 2,3,4,6-Tetrachlorophenol | 58-90-2 | Oral | Increased liver weights and centrilobular hypertrophy | RFD | 3 x 10 -2 mg/kg-day |
| Tetrachlorovinphos | 961-11-5 | Oral | Reduced body weight gain, increased liver and kidney weights, and RBC ChE inhibition | RFD | 3 x 10 -2 mg/kg-day |
| Tetraethyl lead | 78-00-2 | Oral | Histopathology of liver and thymus | RFD | 1 x 10 -7 mg/kg-day |
| Tetrahydrofuran | 109-99-9 | Inhalation | Increased liver weight and centrilobular cytomegaly, CNS effects (narcosis) | RFC | 2 mg/m3 |
| Triallate | 2303-17-5 | Oral | Increased hemosiderin deposition, serum alkaline phosphatase, and liver weight in females | RFD | 1.3 x 10 -2 mg/kg-day |
| Triasulfuron | 82097-50-5 | Oral | Centrilobular hepatocytomegaly in males | RFD | 1 x 10 -2 mg/kg-day |
| 1,2,4-Tribromobenzene | 615-54-3 | Oral | Increased liver-to-body weight ratio and hepatic microsomal enzyme induction | RFD | 5 x 10 -3 mg/kg-day |
| Trichloroacetic acid | 76-03-9 | Oral | Hepatocellular necrosis | RFD | 2 x 10 -2 mg/kg-day |
| 1,1,1-Trichloroethane | 71-55-6 | Inhalation | Liver histopathologic changes | RFC | 5 mg/m3 |
| 1,1,1-Trichloroethane | 71-55-6 | Inhalation | Liver histopathologic changes | RFC | 5 mg/m3 |
| 2,4,5-Trichlorophenol | 95-95-4 | Oral | Liver and kidney pathology | RFD | 1 x 10 -1 mg/kg-day |
| 2(2,4,5-Trichlorophenoxy) propionic acid (2,4,5-TP) | 93-72-1 | Oral | Histopathological changes in liver | RFD | 8 x 10 -3 mg/kg-day |
| 1,2,3-Trichloropropane | 96-18-4 | Oral | Increased absolute liver weight in male rats | RFD | 4 x 10 -3 mg/kg-day |
| 1,1,2-Trichloropropane | 598-77-6 | Oral | Mild lesions in liver, kidney and thyroid | RFD | 5 x 10 -3 mg/kg-day |
| Trifluralin | 1582-09-8 | Oral | Increased liver weights; increase in methemoglobin | RFD | 7.5 x 10 -3 mg/kg-day |
| 2,4,6-Trinitrotoluene (TNT) | 118-96-7 | Oral | Liver effects | RFD | 5 x 10 -4 mg/kg-day |
| Vinyl bromide | 593-60-2 | Inhalation | Hypertrophy, basophilic and eosinophilic foci, in the liver | RFC | 3 x 10 -3 mg/m3 |
| Vinyl chloride | 75-01-4 | Oral | Liver cell polymorphism | RFD | 3 x 10 -3 mg/kg-day |
| Vinyl chloride | 75-01-4 | Inhalation | Liver cell polymorphism | RFC | 1 x 10 -1 mg/m3 |